The role of dolutegravir in the management of HIV infection

References

• Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsWashington, DCDepartment of Health and Human Services Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Updated May 1, 2014Accessed October 8, 2014
   Google Scholar
• SaxPEZolopaABrarITenofovir alafenamide vs tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 studyJ Acquir Immune Defic Syndr2014671525824872136
   PubMedGoogle Scholar
• Gilead SciencesStudy to evaluate the safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in HIV-1 positive, antiretroviral treatment-naïve adults Available from: http://clinicaltrials.gov/ct2/show/NCT1797445. NLM Identifier: NCT1797445Accessed January 5, 2015
   Google Scholar
• Gilead SciencesPhase 3 open-label study to evaluate switching from optimized stable antiretroviral regimens containing darunavir to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single tablet regimen plus darunavir in treatment experienced HIV-1 positive adults Available from: http://clinicaltrials.gov/ct2/show/NCT1968551. NLM Identifier: NCT1968551Accessed January 5, 2015
   Google Scholar
• Gilead SciencesOpen-label study to evaluate switching from a TDF-containing combination regimen to a TAF-containing combination single table regimen in virologically-suppressed, HIV-1 positive subjects Available from: http://clinicaltrials.gov/ct2/show/NCT1815736. NLM Identifier: NCT1815736Accessed January 5, 2015
   Google Scholar
• Gilead SciencesSwitch study to evaluate F/TAF in HIV-1 positive participants who are virologically suppressed on regimens containing TDF/FTC Available from: http://clinicaltrials.gov/ct2/show/NCT2121795. NLM Identifier: NCT2121795Accessed January 5, 2015
   Google Scholar
• Viiv HealthcareDose ranging study of GSK1265744 plus nucleoside reverse transcriptase inhibitors for induction of Human Immunodeficiency Virus-1 virologic suppression followed by virologic suppression maintenance by GSK1265744 plus rilpivirine Available from: http://clinicaltrials.gov/ct2/show/NCT1641809. NLM Identifier: NCT1641809Accessed January 5, 2015
   Google Scholar
• Viiv HealthcareA phase 2b study to evaluate a long-acting intramuscular regimen for maintenance of virologic suppression (following induction with an oral regimen of GK1265744 and abacavir/lamivudine) in Human Immunodeficiency Virus Type 1 infected, antiretroviral therapy-naïve adult subjects Available from: http://clinicaltrials.gov/ct2/show/NCT2120352. NLM Identifier: NCT2120352Accessed January 5, 2015
   Google Scholar
• AndrewsCDSpreenWRMohriLong-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virusScience20143431151115424594934
   PubMed Web of Science ®Google Scholar
• JohnsBAKawasujiTWeatherheadJGCarbamoyl pyridine HIV-1 integrase inhibitors 3: a diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744)J Med Chem2013565901591610.1021/jm400645w23845180
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyProduct information for Tivicay2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002753/WC500160680.pdfAccessed November 6, 2014
   Google Scholar
• HareSSmithSJMétifiotMStructural and functional analysis of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572)Mol Pharmacol201180565572doi:10.1124/mol.111.073189.21719464
   PubMed Web of Science ®Google Scholar
• SongIBorlandJChenSEffect of food on the pharmacokinetics of the integrase inhibitor dolutegravirAntimicrob Agents Chemother2012561627162910.1128/AAC.05739-1122183173
   PubMed Web of Science ®Google Scholar
• Tivicay (dolutegravir) tablet [product information]Research Triangle Park, NCGlaxoSmithKline2014
   Google Scholar
• LetendreSLMillsAMTashimaKTING116070: A study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, ART-naïve subjectsClin Infect Dis20145910321037doi:10.1093/cid/ciu477.24944232
   PubMed Web of Science ®Google Scholar
• GreenerBNPattersonKBPrinceHMDolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosingJ Acquir Immune Defic Syndr2013643944doi:10.1097/QAI.0b013e31829ed7a4.23945251
   PubMed Web of Science ®Google Scholar
• AdamsJLPattersonKBPrinceHMSingle and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative womenAntivir Ther20131810051013doi:10.3851/IMP2665.23899439
   PubMed Web of Science ®Google Scholar
• ReeseMJSavinaPMGenerauxGTIn vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitorDrug Metab Dispos201341353361doi:10.1124/dmd.112.048918.23132334
   PubMed Web of Science ®Google Scholar
• CastellinoSMossLWagnerDMetabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humansAntimicrob Agents Chemother20135735363546doi:10.1128/AAC.00292-13.23669385
   PubMed Web of Science ®Google Scholar
• MinSSloanLDeJesusEAntiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adultsAIDS20112517371745doi:10.1097/QAD.0b013e32834a1dd9.21716073
   PubMed Web of Science ®Google Scholar
• ChenSSt JeanPBorlandJEvaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokineticsPharmacogenomics201415916doi:10.2217/pgs.13.190.24329186
   PubMed Web of Science ®Google Scholar
• SongIHBorlandJSavinaPMPharmacokinetics of single-dose dolutegravir in HIV-seronegative subjects with moderate hepatic impairment compared to healthy matched controlsClin Pharmacol Drug Dev20132342348doi:10.1002/cpdd.55.
   PubMed Web of Science ®Google Scholar
• KoteffJBorlandJChenSA phase 1 study to evaluate dolutegravir’s effect on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjectsBr J Clin Pharmacol201375990996doi:10.1111/j.1365-2125.2012.0440.x.22905856
   PubMed Web of Science ®Google Scholar
• SongIMinSSBorlandJLack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjectsJ Acquir Immune Defic Syndr201055365367doi:10.1097/QAI.0b013e3181e67909.20585260
   PubMed Web of Science ®Google Scholar
• SongIBorlandJChenSEffect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572Br J Clin Pharmacol201172103108doi:10.1111/j.1365-2125.2011.03947.x.21342217
   PubMed Web of Science ®Google Scholar
• SongIMinSSBorlandJThe effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participantsJ Clin Pharmacol201151237242doi:10.1177/0091270010371113.20489027
   PubMed Web of Science ®Google Scholar
• SongIBorlandJLouYEffects of the enzyme inducers, tipranavir and efavirenz, on the pharmacokinetics of the integrase inhibitor, dolutegravir (S/GSK1349572) [abstract O-02]Paper presented at: 12th International Workshop on Clinical Pharmacology of HIV TherapyApril 13–15, 2011Miami, FL
   Google Scholar
• SongIBorlandJChenSEffect of fosamprenavir/ritonavir on the pharmacokinetics of the integrase inhibitor, dolutegravir, in healthy subjects [abstract A1-1727]Paper presented at: 51st Annual Interscience Conference on Antimicrobial Agent and ChemotherapySeptember 17–20, 2011Chicago, IL
   Google Scholar
• SongIBorlandJMinSEffects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravirAntimicrob Agents Chemother20115535173521doi:10.1128/AAC.00073-11.21555764
   PubMed Web of Science ®Google Scholar
• FordSLGouldEChenSLack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744Antimicrob Agents Chemother2014571154725477doi:10.1128/AAC.01235-13.23979733
   PubMed Web of Science ®Google Scholar
• DooleyKESayrePBorlandJSafety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among health subjectsJ Acquir Immune Defic Syndr2013622127doi:10.1097/QAI.0b013e318276cda9.23075918
   PubMed Web of Science ®Google Scholar
• PatelPSongIBorlandJPharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteersJ Antimicrob Chemother2011661567157210.1093/jac/dkr13921493648
   PubMed Web of Science ®Google Scholar
• SongIBorlandJAryaNWynneBPiscitelliSThe effect of calcium and iron supplements on the pharmacokinetics of dolutegravir in healthy subjectsPaper presented at: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis TherapyMay 19–21, 2014Washington, DC Abstract P_13
   Google Scholar
• CanducciFCeresolaERBoeriECross-resistance profile of the novel Integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravirJ Infect Dis201120418111815doi:10.1093/infdis/jir636.21984737
   PubMed Web of Science ®Google Scholar
• UnderwoodMRJohnsBASatoAThe activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adultsJ Acquir Immune Defic Syndr20123297301doi:10.1097/QAI.0b013e31826bfd02.22878423
   PubMed Web of Science ®Google Scholar
• DeAndaFHightowerKENolteRTDolutegravir interactions with HIV-1 Integrase-DNA: structural rationale for drug resistance and dissociation kineticsPLoS One20138e77448doi:10.1371/journal.pone.0077448.24146996
   PubMed Web of Science ®Google Scholar
• KobayashiMYoshinagaTSekiTIn vitro antiretroviral properties of S/GSK1349572, a next generation HIV integrase inhibitorAntimicrob Agents Chemother201155813821doi:10.1128/AAC.01209-10.21115794
   PubMed Web of Science ®Google Scholar
• van LunzenJMaggioloFArribasJROnce-daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naïve adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialLancet Infect Dis201212111118doi:10.1016/S1473-3099(11)70290-0.22018760
   PubMed Web of Science ®Google Scholar
• RaffiFRachlisAStellbrinkHJOnce-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyLancet2013381735743doi:10.1016/S0140-6736(12)61853-4.23306000
   PubMed Web of Science ®Google Scholar
• WalmsleySLAntelaAClumeckNDolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infectionN Eng J Med201336918071818doi:10.1056/NEJMoa1215541.
   PubMed Web of Science ®Google Scholar
• ClotetBFeinbergJvan LunzenJOnce-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b studyLancet201438322222231doi:10.1016/S0140-6736(14)60084-2.24698485
   PubMed Web of Science ®Google Scholar
• CahnPPozniakALMingroneHDolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyLancet2013382700708doi:10.1016/S0140-6736(13)61221-0.23830355
   PubMed Web of Science ®Google Scholar
• EronJJBonaventuaCDurantJSafety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING studyJ Infect Dis2013207740748doi:10.1093/infdis/jis750.23225901
   PubMed Web of Science ®Google Scholar
• CastagnaAMaggioloFPencoGDolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase 3 VIKING-3 StudyJ Infect Dis2014210354362doi:10.1093/infdis/jiu051.24446523
   PubMed Web of Science ®Google Scholar
• MaletIGimferrer ArriagaLArteseANew raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitorsJ Antimicrob Chemother20146921182122doi:10.1093/jac/dku095.24710029
   PubMed Web of Science ®Google Scholar
• HurtCBSebastianJHickCBEronJJResistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009–2012Clin Infect Dis201458423431doi:10.1093/cid/cit697.24145878
   PubMed Web of Science ®Google Scholar
• RaffiFJaegerHQuiros-RoldanEOnce-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from randomized, double-blind, non-inferiority trialLancet20131392793524074642
   PubMed Web of Science ®Google Scholar
• WalmsleySBerenguerJKhuong-JossesMDolutegravir regimen statistically superior to efavirenz/tenofovir/emtricitabine: 96-week results from the SINGLE study (ING114467)Paper presented at: 21st Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2014Boston, MA
   Google Scholar
• PappaKBaumgartenAFelizartaFDoltegravir + abacavir/lamivudine once dialy superior to tenofovir/emtricitabine/efavirenz in treatment naïve HIV subjects: 144-week results from SINGLE (INH114467)Presented at: 54th Annual Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 5–9, 2014Washington DC Abstract H-647a
   Google Scholar
• Viiv HealthcareA study to determine safety and efficacy of dolutegravir/abacavir/lamivudine in Human Immunodeficiency Virus-1 infected antiretroviral therapy naïve women Available from: http://clinicaltrials.gov/ct2/show/NCT1910402. NLM Identifier: NCT1910402Accessed January 5, 2015
   Google Scholar
• NicholsGLazzarinAMaggioloFPhase 3 assessment of dolutegravir (DTG) 50 mg twice daily (BID) in HIV-1-infected subjects with raltegraivr (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of all 183 subjects enrolled (abstract TULBPE19)Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and PreventionJune 30–July 3, 2013Kuala Lumpur, Malaysia
   Google Scholar
• VavroCLHuangJAvatapallyCMinSAit-KhaledMDurable efficacy and limited integrase resistance evolution in subjects receiving dolutegravir after failing prior integrase inhibititor (INI) regimens: week 48 results from VIKING-3 (abstract O_10)Presented at: 12th European Meeting on HIV and Hepatitis – Treatment Strategies and Antiviral Drug ResistanceMarch 26–28, 2014Barcelona, Spain
   Google Scholar
• VianiRMAlveroCFentonTSafety, pharmacokintetics, and efficacy of dolutegravir in treatment experienced HIV positive childrenPoster presented at: 21st Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2014Boston, MA
   Google Scholar
• VianiRMAlveroCFentonTSafety and efficacy of dolutegravir in HIV treatment-experienced adolescents: 48-week resultsPoster presented at: 21st Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2014Boston, MA
   Google Scholar
• AiroldiMZaccarelliMBisiLOne-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life in HIV-infected subjectsPatient Prefer Adherence2010411512520517472
   PubMed Web of Science ®Google Scholar
• ParientiJJBangsbergDRVerdonRGardnerEMBetter adherence with once-daily antiretroviral regimens: a meta-analysisClin Infect Dis20094848448819140758
   PubMed Web of Science ®Google Scholar
• StoneVEJordanJTolsonJMillerRPilonTPerspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapyJ Acquir Immuni Defic Syndr2004363808816
   PubMed Web of Science ®Google Scholar
• WilligJHAbromsSWestfallAOIncreased regimen durability in the era of once daily fixed-dose combination antiretroviral therapyAIDS200822151951196018784459
   PubMed Web of Science ®Google Scholar
• MurrayMGoodwinBHaginsDMeasuring patient views of HIV treatments: comparing dolutegravir with darunavir/r in the FLAMINGO studyPresented at: 20th International AIDS ConferenceJuly 20–25, 2014Melbourne, Australia
   Google Scholar